Israeli AI Innovator CytoReason Raises $80 Million for Healthcare Advancements
%2Fuploads%2Fpr%2520articles%2F2024%2F07%2F17_5cytoreason.jpg&w=3840&q=75)
Israeli AI company CytoReason, known for developing advanced disease models, announced on Wednesday that it has secured $80 million in a private funding round. The round saw participation from notable investors, including Nvidia, Pfizer, Thermo Fisher, and venture capital firm OurCrowd.
With this new funding, CytoReason plans to broaden the application of its AI-driven models to cover more medical conditions and enhance its proprietary molecular and clinical data. Additionally, the company intends to establish a new office in Cambridge, Massachusetts, later this year.
In 2022, Pfizer deepened its partnership with CytoReason by investing $20 million, with the potential for the total investment to reach $110 million by 2027. Pfizer’s Chief Scientific Officer, Mikael Dolsten, emphasized the transformative potential of AI in healthcare, highlighting the collaboration's role in advancing drug development.
CytoReason's AI platform, which utilizes computational disease models, is currently employed by six of the world’s top ten pharmaceutical companies. These firms rely on CytoReason's technology to make data-driven decisions across various therapeutic areas, including immunology, inflammation, and immuno-oncology.
Source: Steven Scheer / Reuters
CytoReason
CytoReason uses AI to transform biopharma decisions, mapping diseases with extensive data to guide research, compare drugs, and optimize drug portfolios.
%2Fuploads%2Fhealthtech%2Fcover2.jpg&w=3840&q=75)
%2Fuploads%2Fpodcast%2Fspotlights%2FS1E02.png&w=3840&q=75)
%2Fuploads%2Fpodcast%2Fperfect-pitch%2F9.jpg&w=3840&q=75)
%2Fuploads%2Fvideos%2Fmenapt-top-5%2FMENAPT_funding_June2024.jpg&w=3840&q=75)
%2Fuploads%2Fhealthtech%2Fvideos%2FHealthTech_vid21.jpg&w=3840&q=75)
%2Fuploads%2Fhealthtech%2Fvideos%2FHealthTech_vid19.jpg&w=3840&q=75)
%2Fuploads%2Fhealthtech%2Fvideos%2FHealthTech_vid18.jpg&w=3840&q=75)
%2Fuploads%2Fhealthtech%2Fvideos%2FHealthTech_vid17.jpg&w=3840&q=75)
%2Fuploads%2Fhealthtech%2Fvideos%2FHealthTech_vid16.jpg&w=3840&q=75)
%2Fuploads%2Fhealthtech%2Fvideos%2FHealthTech_vid15.jpg&w=3840&q=75)
%2Fuploads%2Fhealthtech%2Fvideos%2FHealthTech_vid14b.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F16_1reeco.jpg&w=3840&q=75)
%2Fuploads%2Farticles%2F2024%2F0910_top-10-isr-h1%2Fisraeli-startups.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F03%2F13_3allohealth.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F03%2F12_1lwh.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F03%2F10_4klaim.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F03%2F04_5nurami.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F24_1lillia.jpg&w=3840&q=75)
%2Fuploads%2Farticles%2F2025%2F0220_seha-virtual-hospital%2Fseha-virtual-hospital.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F18_7nupco.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F16_2exeromedical.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F14_7voyantis.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F12_6appliedai.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F02%2F05_1qeenai.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F27_1i3.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F17_6botika.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F17_3finedine.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F14_teammatesai.jpg&w=3840&q=75)
%2Fuploads%2Fpr%2520articles%2F2025%2F01%2F13_tap.jpg&w=3840&q=75)
